Seminário:
Monitoramento da Resistência do Plasmodium falciparum e Plasmodium vivax aos Antimaláricos em Rondônia e Busca de Novos Esquizonticidas Sanguíneos e Teciduais para Controle e Tratamento da Doença
Chloroquine (CQ), a cost effective antimalarial drug with a relatively good safety profile and therapeutic index, is no longer used by itself to treat patients with Plasmodium falciparum due to CQ-resistant strains. P. vivax, representing over 90% of malaria cases in Brazil, despite reported resistance, is treated with CQ as well as with primaquine to block malaria transmission and avoid late P. vivax malaria relapses. Resistance to CQ and other antimalarial drugs influences malaria control, thus monitoring resistance phenotype by parasite genotyping is helpful in endemic areas.
Data: 11 de setembro
Hora: 13h30
Local: IFSC campus II (sala 1, piso 1)
Palestrante: Anna Caroline Campos Aguiar (Fio Cruz MG)